Eccrine spiradenoma mimicking adenoid cystic carcinoma cytologically (Two case reports and literature review)

2021 ◽  
Author(s):  
Burcu Guzelbey ◽  
Cem Leblebici ◽  
Sevim Baykal Koca
1996 ◽  
Vol 3 (4) ◽  
pp. 336-342 ◽  
Author(s):  
Alexander S.D. Spiers ◽  
Dixie Lee W. Esseltine ◽  
John C. Ruckdeschel ◽  
Jack N.P. Davies ◽  
John Horton

Background Adenoid cystic carcinoma is an uncommon tumor of the salivary gland. Little has been published on the chemotherapy of this neoplasm. Methods The literature on this disease is reviewed, and data from seven unpublished cases are presented. Results Four patients received cyclophosphamide. One responded, and another had pain relief. The literature review did not identify any single drug or combination that might be regarded as the treatment of choice. Conclusions Systematic, multi-institutional studies are required to determine appropriate systemic treatment for metastatic adenoid cystic carcinoma of salivary gland origin.


2021 ◽  
Author(s):  
Satoru Ogane ◽  
Takamasa Kawano ◽  
Chiho Hiraga (Kondo) ◽  
Taiki Suzuki ◽  
Kazuhiko Hashimoto ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Zhongben Tang ◽  
Feng Lin ◽  
Jiarong Xiao ◽  
Xiaojun Du ◽  
Jian Zhang ◽  
...  

Primary pulmonary adenoid cystic carcinomas are salivary tumors that are low-grade malignant and prone to recurrence and metastasis. Surgery is currently the main treatment, but there is no standard with regard to postoperative adjuvant therapy. Adenoid cystic carcinoma is more sensitive to radiotherapy and patients benefit less from chemotherapy, but few studies have focused on targeted therapy, and their conclusions are inconsistent. With respect to primary pulmonary adenoid cystic carcinoma, large-scale studies cannot be conducted due to its low incidence, and studies on the targeted therapy of it are very scarce. A few case reports indicate that targeted therapy can be effective however, suggesting that it may be a good option. The current report is the first on the occurrence of human epidermal growth factor receptor 2 amplification in pulmonary adenoid cystic carcinoma. The patient was treated with pyrotinib for 6 months and achieved stable disease.


Author(s):  
Mohammed El Marjany ◽  
Adil Arsalane ◽  
Hassan Sifat ◽  
Khalid Andaloussi ◽  
Mohamed Oukabli ◽  
...  

2019 ◽  
Vol 9 (3) ◽  
pp. 136-141 ◽  
Author(s):  
Randy C. Bowen ◽  
Huaising C. Ko ◽  
Gregory D. Avey ◽  
Gregory K. Hartig ◽  
Rong Hu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document